Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLFNASDAQ:GLSIOTCMKTS:PFSCFOTCMKTS:PVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$13.60+2.6%$14.16$9.83▼$17.75$131.48M0.8117,536 shs10,396 shsGLSIGreenwich LifeSciences$9.03-1.8%$9.63$8.06▼$18.75$122.99M1.6946,386 shs64,391 shsPFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/APVCTProvectus Biopharmaceuticals$0.08+4.2%$0.09$0.04▼$0.16$31.90M0.79197,753 shs71,900 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands+2.56%-2.86%-0.29%+0.59%-0.58%GLSIGreenwich LifeSciences-1.85%-6.33%-7.29%-21.14%-48.22%PFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%PVCTProvectus Biopharmaceuticals+4.22%-6.39%-4.70%-24.67%-48.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTLFFitLife Brands4.1814 of 5 stars3.73.00.00.01.93.33.1GLSIGreenwich LifeSciences2.2547 of 5 stars3.51.00.00.02.73.30.0PFSCFProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 3.33Buy$20.5050.74% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00331.89% UpsidePFSCFProMetic Life Sciences 0.00N/AN/AN/APVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PVCT, FTLF, GLSI, and PFSCF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$64.47M1.98$0.98 per share13.82$3.93 per share3.46GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/APFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08PVCTProvectus Biopharmaceuticals$620K53.62N/AN/A($0.01) per share-7.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$8.98M$0.8416.1912.36N/A13.85%25.59%15.26%N/AGLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)PFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/APVCTProvectus Biopharmaceuticals-$4.76MN/A0.00∞N/A-815.81%N/A-644.80%8/11/2025 (Estimated)Latest PVCT, FTLF, GLSI, and PFSCF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/APFSCFProMetic Life SciencesN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.191.640.72GLSIGreenwich LifeSciencesN/A1.911.91PFSCFProMetic Life SciencesN/A0.950.71PVCTProvectus BiopharmaceuticalsN/A0.110.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%GLSIGreenwich LifeSciences4.16%PFSCFProMetic Life Sciences0.10%PVCTProvectus Biopharmaceuticals0.05%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.30%GLSIGreenwich LifeSciences51.67%PFSCFProMetic Life SciencesN/APVCTProvectus Biopharmaceuticals12.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionablePVCTProvectus Biopharmaceuticals4420.28 million366.48 millionNot OptionablePVCT, FTLF, GLSI, and PFSCF HeadlinesRecent News About These CompaniesProvectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of StockholdersJune 9, 2025 | globenewswire.comCroatia's Provectus Capital Partners opens office in RomaniaApril 24, 2025 | seenews.comProvectus announces $3M seed financing round for VisiRoseJanuary 15, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | globenewswire.comProvectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmologyDecember 13, 2024 | pharmabiz.comProvectus announces the launch of VisiRoseDecember 12, 2024 | markets.businessinsider.comVisiRose Introduces Revolutionary Therapy for Severe Eye InfectionsDecember 11, 2024 | miamiherald.comProvectus Pharmaceuticals Aligns Leadership with Equity GrantsDecember 6, 2024 | markets.businessinsider.comProvectus Pharmaceuticals to Reveal Key 2024 UpdatesNovember 15, 2024 | markets.businessinsider.comProvectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comProvectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference CallOctober 24, 2024 | manilatimes.netProvectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference CallOctober 10, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual MeetingMay 21, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual MeetingMay 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationApril 16, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal SodiumMarch 27, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and VaccinesMarch 12, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual MeetingMarch 7, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVCT, FTLF, GLSI, and PFSCF Company DescriptionsFitLife Brands NASDAQ:FTLF$13.60 +0.34 (+2.56%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$13.78 +0.18 (+1.29%) As of 06/17/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Greenwich LifeSciences NASDAQ:GLSI$9.03 -0.17 (-1.85%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$9.25 +0.22 (+2.44%) As of 06/17/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.ProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.08 +0.00 (+4.22%) As of 06/17/2025 03:58 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
